echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer's $6.7 billion acquisition of Arena, the latter's share price has risen by more than 80%

    Pfizer's $6.7 billion acquisition of Arena, the latter's share price has risen by more than 80%

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 13, Pfizer announced that it had reached a definitive agreement with Arena to acquire all of the latter’s outstanding shares in cash at a price of US$100 per share, with a total transaction value of approximately US$6.




    Are Na public Division of pipeline products are mainly concentrated in the areas of gastrointestinal diseases, skin diseases and heart disease



    Etrasimod is currently conducting two phase III studies for ulcerative enteritis, one phase II/III study for Crohn's disease, one phase III study for atopic dermatitis, and phase II studies for eosinophilic esophagitis and alopecia areata



    Are na ’s research pipeline also includes two phase II cardiovascular drugs, temanogrel and APD418


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.